ATIM-33. NOA-16: A FIRST-IN-MAN MULTICENTER PHASE I CLINICAL TRIAL OF THE GERMAN NEUROONCOLOGY WORKING GROUP EVALUATING A MUTATION-SPECIFIC PEPTIDE VACCINE TARGETING IDH1R132H IN PATIENTS WITH NEWLY DIAGNOSED MALIGNANT ASTROCYTOMASMichael Platten, Wolfgang Wick, Felix Sahm et al.|Neuro-Oncology|2018Cited by 26
A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).Michael Platten, Wolfgang Wick, Daniela Schilling et al.|Journal of Clinical Oncology|2018Cited by 25
Vaccine Strategies in GliomasMichael Platten, Wolfgang Wick, Lukas Bunse et al.|Current Treatment Options in Neurology|2018Cited by 16
OS6.4 NOA-16: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group evaluating a mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomasMichael Platten, Wolfgang Wick, Daniela Schilling et al.|Neuro-Oncology|2018Cited by 3
Tumoral Interferon Beta Induces an Immune-Stimulatory Phenotype in Tumor-Associated Macrophages in Melanoma Brain MetastasesJulia Gellert, Theresa Bunse|Cancer Research Communications|2024Cited by 3